Benjamin H. Lowentritt, MD, FACS, Details Rationale for an Analysis Assessing How Clinical Factors Influence 18F-rhPSMA-7.3 Detection in Suspected Recurrent Prostate Cancer


The goal of the analysis of the phase 3 SPOTLIGHT trial was to evaluate how clinical factors impact 18F-rhPSMA-7.3 detection rates in a population of patients with suspected recurrent prostate cancer, according to Benjamin H. Lowenritt, MD, FACS.

CancerNetwork® spoke with Benjamin H. Lowenritt, MD, FACS, a practicing urologist at Chesapeake Urology in Baltimore, Maryland, about the design of the phase 3 SPOTLIGHT study (NCT04186845) presented at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.Lowenritt indicated that the purpose was to determine the detection rate of 18F-rhPSMA-7.3 overall and in subgroups of patients with suspected recurrent prostate cancer.


The SPOTLIGHT trial is a study looking at 18F-rhPSMA-7.3, which is a novel PET PSMA agent used to help diagnose patients with prostate cancer. Specifically, the SPOTLIGHT study is looking at those patients who have biochemical recurrence after initial treatments for curative intent—either surgery or radiation—and the data is starting to emerge now that shows that it has good sensitivity and specificity. Specifically, this trial was looking at the overall detection rate, and then specifically the detection rates in certain subgroups.


Lowentritt, B. Impact of clinical factors on 18F-rhPSMA-7.3 detection rates in men with recurrent prostate cancer: findings from the phase 3 SPOTLIGHT study. Presented at 2022 American Society for Radiation Oncology Annual Meeting (ASTRO); October 23-26, 2022; San Antonio, TX. Abstract 1049. Accessed November 3, 2022.

Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.
Related Content